Zacks SCR

NASDAQ: SNES Richard Hantke: Hello everyone. My name is Richard Hantke with Zacks Small Cap Research, and welcome to another episode of our CEO Chat series. Today we've got SenesTech (NASDAQ: SNES), which is involved with rodent birth control solutions, which is kind of interesting. We'll get into that. Zacks has it under coverage with our analyst M. Marin. In her most recent report a few weeks ago, she raised her 2026 revenue target by 20%, and she's got a $3.50 price target on the company.

By Steven Ralston, CFA NYSE: UHAL READ THE FULL UHAL RESEARCH REPORT EXECUTIVE SUMMARY U-Haul Holding Company (NYSE: UHAL, UHAL.B) reported 1Q FY2027 financial results on August 5th after the close. The company delivered record-breaking first-quarter total revenues for the first fiscal quarter, historically the company’s second-strongest seasonal quarter. Total revenues increased 3.2% (or $51.6 million). Top-line growth was achieved across all major business segments.

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH NOTE Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated, measuring tablets and capsules as well as DehydraTECH (DHT) 2.0 and 3.0 formulations.

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) 2026 Meeting.

By Tom Kerr, CFA NASDAQ: BENF READ THE FULL BENF RESEARCH REPORT 1st Quarter 2027 Results (period ending June 30, 2026) On August 14, 2026, Beneficient (NASDAQ: BENF) announced fiscal 1st quarter results for the period ending 6/30/26. Beneficient reported $212.5 million of investments at fair value as of June 30, 2026, up from $195.5 million at the end of the prior fiscal year (3/31/26).

By M. Marin NASDAQ: NVX READ THE FULL NVX RESEARCH REPORT NVX delivered C-sample of material to Panasonic Energy and strengthened its balance sheet as it moves forward to fulfill Panasonic offtake agreement & grow its customer base Novonix (NASDAQ: NVX) is building a North American vertically integrated synthetic graphite supply chain to support multiple sectors.

By David Bautz, PhD NASDAQ: TNXP READ THE FULL TNXP RESEARCH REPORT Business Update $11.0 Million in Net Revenue for Tonmya® in 2Q26 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is continuing the commercial launch of Tonmya® following its approval in August 2025 and commercial launch in November 2025.

By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT New Findings Presented at European Society of Cardiology (ESC) Congress 2026 On September 2, 2026, the CytoSorbents (NASDAQ: CTSO) announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood...

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported second quarter 2026 financial and operational results in an August 31st press release. For the quarter, it produced license revenues of $294,000 and a net loss of $4.3 million. The joint venture (JV) with Hemispherian, which is developing GLIX1, has begun enrolling the second of five cohorts in the ongoing Phase I/IIa trial. It plans to begin dosing a third cohort in September 2026.

By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Launches Strategic Partnering Process for Cardiac Acute Critical Care Franchise Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise that is centered on three commercial pillars.